nach oben

Seminars in Immunopathology

Erschienen in:

01.09.2007 | Review

Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs

verfasst von: Christine E. Becker, Luke A. J. O’Neill

Erschienen in: Seminars in Immunopathology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

The innate immune system relies on a variety of pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs) to sense microbial structures that are present in pathogens. Various levels of crosstalk between the TLR and NLR pathways have been described, most notably the description of a molecular scaffold complex, termed the inflammasome, which requires input from both pathways and leads to the activation of the proinflammatory cytokines interleukin (IL)-1β and IL-18. In certain cases, the inflammatory process becomes dysregulated and chronic inflammatory diseases may develop. Understanding the interactions of the TLR and NLR pathways will provide further clues to the pathogeneses of these diseases and to the development of efficient therapies to combat them.

O’Neill LA (2006) How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 18(1):3–9PubMedCrossRef

Bowie A, O’Neill LA (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol 67(4):508–514PubMed

Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13(5):816–825PubMedCrossRef

Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27(8):352–357PubMedCrossRef

Akira S (2006) TLR signaling. Curr Top Microbiol Immunol 311:1–16PubMedCrossRef

Kawai T et al (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5(10):1061–1068PubMedCrossRef

Honda K et al (2004) Role of a transductional–transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A 101(43):15416–15421PubMedCrossRef

Takaoka A et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434(7030):243–249PubMedCrossRef

Yamamoto M et al (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640–643PubMedCrossRef

10.

Oshiumi H et al (2003) TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta. J Biol Chem 278(50):49751–49762PubMedCrossRef

11.

Meylan E et al (2004) RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 5(5):503–507PubMedCrossRef

12.

Fitzgerald KA et al (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413(6851):78–83PubMedCrossRef

13.

Carty M et al (2006) The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 7(10):1074–1081PubMedCrossRef

14.

Liew FY et al (2005) Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5(6):446–458PubMedCrossRef

15.

Ting JP, Kastner DL, Hoffman HM (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6(3):183–195PubMedCrossRef

16.

Werts C, Girardin SE, Philpott DJ (2006) TIR, CARD and PYRIN: three domains for an antimicrobial triad. Cell Death Differ 13(5):798–815PubMedCrossRef

17.

Barnich N et al (2005) Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition. J Cell Biol 170(1):21–26PubMedCrossRef

18.

Kummer JA et al (2007) Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues, suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 55(5):443–452PubMedCrossRef

19.

LeibundGut-Landmann S et al (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34(6):1513–1525PubMedCrossRef

20.

Chamaillard M, Inohara,N, Nunez G (2004) Battling enteroinvasive bacteria: Nod1 comes to the rescue. Trends Microbiol 12(12):529–532PubMedCrossRef

21.

Girardin SE et al (2003) Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300(5625):1584–1587PubMedCrossRef

22.

Inohara N et al (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J Biol Chem 278(8):5509–5512PubMedCrossRef

23.

Girardin SE et al (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278(11):8869–8872PubMedCrossRef

24.

Meylan E, Tschopp J (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 30(3):151–159PubMedCrossRef

25.

Kobayashi KS et al (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307(5710):731–734PubMedCrossRef

26.

Girardin SE et al (2001) CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2(8):736–742PubMedCrossRef

27.

Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38(2):240–244PubMedCrossRef

28.

Agostini L et al (2004) NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20(3):319–325PubMedCrossRef

29.

Park JH et al (2007) RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 178(4):2380–2386PubMed

30.

Mariathasan S et al (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430(6996):213–218PubMedCrossRef

31.

Sutterwala FS et al (2006) Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24(3):317–327PubMedCrossRef

32.

Watanabe H et al (2007) Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol (in press)

33.

O’Neill LA (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2000(44):RE1

34.

Martinon F, Tschopp J (2005) NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26(8):447–454PubMedCrossRef

35.

Takeuchi O et al (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11(4):443–451PubMedCrossRef

36.

Travassos LH et al (2004) Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 5(10):1000–1006PubMedCrossRef

37.

Fritz JH et al (2005) Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 35(8):2459–2470PubMedCrossRef

38.

Li J et al (2004) Regulation of IL-8 and IL-1beta expression in Crohn’s disease associated NOD2/CARD15 mutations. Hum Mol Genet 13(16):1715–1725PubMedCrossRef

39.

van Heel DA et al (2005) Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 35(8):2471–2476PubMedCrossRef

40.

van Heel DA et al (2005) Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 365(9473):1794–1796PubMedCrossRef

41.

van Heel DA et al (2005) Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn’s disease. Gut 54(11):1553–1557PubMedCrossRef

42.

Uehara A et al (2005) Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7(1):53–61PubMedCrossRef

43.

Tada H et al (2005) Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73(12):7967–7976PubMedCrossRef

44.

Ferwerda G et al (2005) NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog 1(3):279–285PubMedCrossRef

45.

Watanabe H et al (2004) Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22(5):460–466PubMedCrossRef

46.

Rosenstiel P et al (2003) TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 124(4):1001–1009PubMedCrossRef

47.

Takahashi Y et al (2006) Up-regulation of NOD1 and NOD2 through TLR4 and TNF-alpha in LPS-treated murine macrophages. J Vet Med Sci 68(5):471–478PubMedCrossRef

48.

Chen CM et al (2004) Reciprocal cross-talk between Nod2 and TAK1 signaling pathways. J Biol Chem 279(24):25876–25882PubMedCrossRef

49.

Kufer TA, Sansonetti PJ (2007) Sensing of bacteria: NOD a lonely job. Curr Opin Microbiol 10(1):62–69PubMedCrossRef

50.

Chin AI et al (2002) Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416(6877):190–194PubMedCrossRef

51.

Kobayashi K et al (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416(6877):194–199PubMedCrossRef

52.

Lu C et al (2005) Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. J Biol Chem 280(16):16278–16283PubMedCrossRef

53.

Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40PubMedCrossRef

54.

Kahlenberg JM et al (2005) Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol 175(11):7611–7622PubMed

55.

Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 25(21):5071–5082PubMedCrossRef

56.

Solle M et al (2001) Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 276(1):125–132PubMedCrossRef

57.

Miao EA et al (2006) Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7(6):569–575PubMedCrossRef

58.

Miggin SM et al (2007) NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1. Proc Natl Acad Sci U S A 104(9):3372–3377PubMedCrossRef

59.

Grenier JM et al (2002) Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett 530(1–3):73–78PubMedCrossRef

60.

Wang L (2002) PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem 277(33):29874–29880PubMedCrossRef

61.

O’Connor W Jr et al (2003) Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappa B suppressive properties. J Immunol 171(12):6329–6333PubMed

62.

Williams KL et al (2005) The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem 280(48):39914–39924PubMedCrossRef

63.

Franchi L et al (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7(6):576–582PubMedCrossRef

64.

Berdeli A et al (2005) TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 83(7):535–541PubMedCrossRef

65.

Ogus AC et al (2004) The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 23(2):219–223PubMedCrossRef

66.

Moore CE et al (2004) Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 11(6):1194–1197PubMedCrossRef

67.

Kang TJ, Chae GT (2001) Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 31(1):53–58PubMedCrossRef

68.

Agnese DM et al (2002) Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186(10):1522–1525PubMedCrossRef

69.

Child NJ et al (2003) Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 31(Pt 3):652–653PubMedCrossRef

70.

Minoretti P et al (2006) Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer’s disease. Neurosci Lett 391(3):147–149PubMedCrossRef

71.

Zheng SL et al (2004) Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 64(8):2918–2922PubMedCrossRef

72.

Hawn TR et al (2003) A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires’ disease. J Exp Med 198(10):1563–1572PubMedCrossRef

73.

Tantisira K et al (2004) Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 5(5):343–346PubMedCrossRef

74.

Abinun M (1995) Ectodermal dysplasia and immunodeficiency. Arch Dis Child 73(2):185PubMedCrossRef

75.

Ku CL et al (2005) Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 203:10–20PubMedCrossRef

76.

Picard C et al (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299(5615):2076–2079PubMedCrossRef

77.

Medvedev AE et al (2002) Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169(9):5209–5216PubMed

78.

Jefferies CA, O’Neill LA (2004) Bruton’s tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? Immunol Lett 92(1–2):15–22PubMedCrossRef

79.

Khor CC et al (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39(4):523–528PubMedCrossRef

80.

Kiechl S et al (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347(3):185–192PubMedCrossRef

81.

Palmer SM et al (2003) The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 168(6):628–632PubMedCrossRef

82.

Rudofsky G Jr et al (2004) Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care 27(1):179–183PubMedCrossRef

83.

Andersen-Nissen E et al (2005) Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A 102(26):9247–9252PubMedCrossRef

84.

Andersen-Nissen E et al (2007) A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. J Exp Med 204(2):393–403PubMedCrossRef

85.

Fortune SM et al (2004) Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol 172(10):6272–6280PubMed

86.

Rosenstiel P, Till A, Schreiber S (2007) NOD-like receptors and human diseases. Microbes Infect 9(5):648–657PubMedCrossRef

87.

Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87(6):2095–2147PubMed

88.

Cook DN, Pisetsky DS, Schwartz DA (2004) Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5(10):975–979PubMedCrossRef

89.

Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7(3):179–190PubMedCrossRef

Titel: Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs
verfasst von: Christine E. Becker
Luke A. J. O’Neill
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 3/2007
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-007-0081-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

The role of the inflammasome in cellular responses to toxins and bacterial effectors

NALP Inflammasomes: a central role in innate immunity

Strategies that modulate inflammasomes—insights from host–pathogen interactions

The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self

The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation